I just don't see anything good coming out of this. 052 is a crap with no indication of working either in diabetics and RA. Neuprex has been going on for ages and is a waste of money. BCE patent is expiring. Royalty is already pegged for debt. FTEs and collaborations are losing money. Tell me where is the value? I just don't see it.
U.S. BCE patents expire at the end of 2014 (Lucentis is made in the US, so XOMA gets money on european sales). Some of the newer tech licenses are structured so that XOMA receives royalties for 10 years post approval, irrespective of the patent expiration date.
Tanezumab is in P3 (PFE drug with large indication)
HE tech drugs pay much higher royalties (AVEO 299 uses this and interim data will be presented on April 18) Takeda just signed an HE license.
Gov contract should be entering clinical trial (I animal trial and that is it) and if efficacy is shown, XOMA will receive ~$150mm every 2 years for stockpiling.
Collaborations are reaching the stage where initial royalyies should begin.
Double digit royalties on HCD 122 and another un-named NVS drug
You are respectable because you are talking about facts.
I read the P1 data on 052 and I don't believe it is working. I also read preclinical data of 052 on RA and I don't believe it is working either. I would not bet anything on this molecule regardless of 300 fmol affinity. It is not working.